8-K: Ekso Bionics Reports First Quarter 2024 Financial Results, Achieves Medicare Reimbursement Milestone

Ekso Bionics announced its first quarter 2024 financial results, highlighted by a Medicare reimbursement determination and a gross margin of 52%.

Summary

• Ekso Bionics reported a revenue of $3.8 million for the first quarter of 2024, a decrease from $4.1 million in the same period of 2023.
• The company achieved a gross margin of 52% in Q1 2024, up from 49% in Q1 2023, primarily due to lower device and service costs.
• Sales and marketing expenses decreased to $1.8 million, compared to $2.1 million in the same quarter last year, due to lower headcount.
• General and administrative expenses also decreased to $2.3 million from $3.2 million, due to reduced legal activity, lower headcount, and the absence of acquisition costs.
• The net loss for the quarter was $3.4 million, or $0.20 per share, an improvement from a net loss of $4.4 million, or $0.33 per share, in the first quarter of 2023.
• Ekso Bionics sold 29 EksoHealth units in the first quarter of 2024.
• Cash and restricted cash increased slightly to $8.8 million as of March 31, 2024, compared to $8.6 million at the end of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the Medicare reimbursement approval and improved gross margin, but tempered by the revenue decrease and continued net loss.

Positives

• The company secured a final Medicare reimbursement determination for Ekso Indego Personal, which is a significant step for commercialization.
• Gross margin increased to 52% due to lower device and service costs.
• Sales and marketing expenses decreased due to lower headcount.
• General and administrative expenses decreased due to reduced legal activity and lower headcount.
• The net loss improved compared to the same quarter last year.

Negatives

• Revenue decreased to $3.8 million from $4.1 million in the same quarter of the previous year.
• The company still reported a net loss of $3.4 million for the quarter.

Risks

• The company's future performance is subject to risks including obtaining adequate financing, achieving market acceptance of its products, and managing competition.
• The company's ability to maintain or expand Medicare reimbursement is critical to its success.
• The company's ability to successfully integrate the HMC business and its personnel is a risk.
• Disruptions in the company's supply chain could negatively impact results.

Future Outlook

The company remains focused on developing the market for Indego Personal and strengthening relationships with network operators for Enterprise devices to maximize growth potential.

Management Comments

• Scott Davis, Chief Executive Officer of Ekso Bionics, stated that the CMS final payment determination for Ekso Indego Personal marked a pivotal step in their commercial strategy.
• Management is focused on further developing the market for Indego Personal and strengthening relationships with network operators for Enterprise devices.

Industry Context

The announcement is relevant to the broader exoskeleton technology industry, particularly in the medical and rehabilitation sectors, where reimbursement approvals are critical for market adoption. The CMS decision is a positive signal for the company's growth prospects.

Comparison to Industry Standards

• Ekso Bionics competes with companies like ReWalk Robotics and Cyberdyne in the exoskeleton market.
• ReWalk Robotics reported Q4 2023 revenue of $1.8 million and a gross profit of $0.7 million, while Cyberdyne reported a revenue of ¥1.1 billion for the year ended March 2023. Ekso's Q1 2024 revenue of $3.8 million and gross profit of $2.0 million is higher than ReWalk's most recent results.
• The 52% gross margin achieved by Ekso Bionics is a positive sign, indicating efficient cost management compared to some competitors.

Stakeholder Impact

• Shareholders may view the Medicare reimbursement approval positively, but the revenue decrease and net loss may cause concern.
• Employees may be impacted by the reduced headcount, but the company's progress may provide job security.
• Customers may benefit from the increased availability of Ekso Bionics products due to the reimbursement approval.
• Suppliers may see increased demand for components as the company expands its market reach.

Next Steps

• The company will continue to develop the market for Indego Personal.
• Ekso Bionics will focus on strengthening relationships with network operators for Enterprise devices.
• Management will host a conference call to discuss the financial results and business developments.

Key Dates

Keywords

Ekso Bionics, exoskeleton, medical devices, Medicare reimbursement, financial results, gross margin, net loss, EksoHealth, Indego Personal